Drug Trial Radar · NCT02142751
Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli
Last checked: Nov 19, 2026Latest source record: Aug 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Jul 2014
Primary completion
Dec 2018
Study completion Mar 2019
Sponsor
- Lead sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en SevillaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Spanish Network for Research in Infectious Diseases
- First posted
- May 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Enterobacterieaceae (and specially Escherichia coli) showing resistance due to multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by chromosomal mechanisms have spread worldwide during the last decades. This is important because many of these isolates are also resistant to other first-line agents such as fluoroquinolones or aminoglycosides, leaving few available options for therapy, and this condition is associated with increased morbidity- mortality and length of hospital stay. While carbapenems are considered the drugs of choice for multidrug-resistant Escherichia coli and AmpC producers, recent data suggests that certain alternatives may be suitable for some types of infections. At the present time, finding therapeutic alternatives to carbapenems and cephalosporins for the treatment of invasive infections due to multidrug-resistant Escherichia coli is critical. Fosfomycin was discovered more than 40 years ago but was not investigated according to present standards, and thus is not used in clinical practice except in desperate situations. It is one of the so-considered neglected antibiotics with high potential interest for the future. With the aim of demonstrate the clinical non-inferiority of intravenous fosfomycin compared to meropenem or ceftriaxone in the treatment of bacteraemic urinary tract infections caused by multidrug-resistant Escherichia coli . The investigators propose a "real practise" randomised, controlled, multicentre phase III clinical trial to compare the clinical and microbiological efficacy and safety of intravenous fosfomycin (4 grammes every 6 hours) with meropenem (1 gramme every 8 hours) or ceftriaxone (1 gramme every 24 hours) as targeted therapy of the previously specified infection; change to oral therapy according to predefined options is allowed in both arms after 5 days. Follow-up for the study is planned up to 60 days.
Conditions
- Infection Due to ESBL Escherichia Coli
Interventions
Fosfomycin sodium intravenousDrug
4g every 6 hours iv (60 min infusion)
Meropenem intravenousDrug
1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
Ceftriaxone intravenousDrug
1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical and microbiological cure rateTime frame: Day 5-7 after end of treatment (test of cure)
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Hospital Marina Baixa
Alicante, Spain
Hospital General Universitario de Alicante
Alicante, Spain
Hospital Parc Salud Mar
Barcelona, Spain
Hospital de la Santa Creu i San Pau
Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Universitario de Bellvitge
Barcelona, Spain
Hospital de Cruces
Bilbao, Spain
Hospital Universitario de Burgos
Burgos, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Central de Asturias
Oviedo, Spain
Hospital Son Espases
Palma de Mallorca, Spain
Hospital Marqués de Valdecilla
Santander, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Hospital Royo Villanova
Zaragoza, Spain
Hospital Mutua de Terrassa
Terrassa, Barcelona, Spain
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Gran Canarias, Spain
Hospital Arnau de Vilanova
Vilanova, Lleida, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
El Palmar, Murcia, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.